The SoloPath® Re-Collapsible Access System is indicated for percutaneous insertion into the femoral artery over a guidewire and, once expanded, to provide a guide for catheters and/or devices introduced into the femoral artery. The device may also be used to expand femoroiliac artery lesions to facilitate its use as an Access System.

Device Description

The SoloPath Re-Collapsible Access System is a sterile, single-use device that consists of a flexible, reinforced polymer sheath and specially folded, radially-collapsed distal end (the Sheath) pre-mounted over a central balloon dilatation catheter (the Expander), and equipped with a proximal hub assembly incorporating a hemostasis valve.

The SoloPath assembly is inserted percutaneously over a guidewire, with the deflated Expander in place. Once positioned into the vasculature and inflated with liquid, the Expander balloon exerts a controlled radial force, enlarging the folded distal region of the Sheath and surrounding anatomy. The Expander balloon is deflated and the Expander is removed leaving a central lumen extending from the proximal end to the distal end of the Sheath, which maintains its expanded size by means of malleable distal reinforcement.

The SoloPath Re-Collapsible Access System features an integrated external collapsible outer jacket which is pressurized with liquid under low pressure prior to removal, collapsing the outer sheath diameter for ease of removal. The Sheath is designed: 1) as a guide for catheters and/or devices introduced into the femoral artery and 2) to dilate stenosed femoro-iliac vessels as an adjunct to its primary function.

The principles of operation for the subject SoloPath Re-Collapsible Access System are identical to those of the currently cleared SoloPath Re-Collapsible Access System (K121404). There are no changes to the insertion, deployment, or removal of the device as a result of this secondary indication.

AI/ML Overview

This submission is a 510(k) for the SoloPath Re-Collapsible Access System, which is an intravascular catheter. The 510(k) is for the addition of a secondary indication for use. Therefore, the information provided focuses on non-clinical performance and substantial equivalence to a predicate device, rather than a traditional study with strict acceptance criteria for AI model performance.

Here's an analysis based on the provided document:

1. Table of Acceptance Criteria and Reported Device Performance

Since this is a 510(k) for a medical device and not an AI/ML product, the "acceptance criteria" are tied to demonstrating substantial equivalence to a predicate device and adherence to relevant ISO standards, rather than metrics like sensitivity or specificity. The "reported device performance" refers to the successful completion of specified tests.

Acceptance Criteria (related to ISO Standards and Predicate Equivalence)	Reported Device Performance
Radio-detectability: Conform to ISO 10555-4, Section 4.2	Successfully completed.
Designation of nominal size: Conform to ISO 10555-4, Section 4.3	Successfully completed.
Balloon rated burst pressure (RBP): Conform to ISO 10555-4, Section 4.4.1, Annex A	Successfully completed.
Balloon fatigue; freedom from leakage and damage on inflation: Conform to ISO 10555-4, Section 4.4.2, Annex B	Successfully completed.
Balloon deflation time: Conform to ISO 10555-4, Section 4.4.3, Annex C	Successfully completed.
Biocompatibility: No changes from original testing (K121404) in accordance with ISO 10993.	Original testing reviewed under K121404 remains valid as no changes to materials, sterilization, or packaging.
Sterilization: No changes from original process (K121404) in accordance with ISO 11135-1:2007 to achieve SAL of 10-6.	Original sterilization process and procedure remain valid as no changes have been made.
Risk Analysis: Conducted in accordance with ISO 14971, with new risks adequately captured and mitigated.	Completed, new risks assessed and mitigated.
Substantial Equivalence: Demonstrate equivalence in intended use, technology/principal of operation, materials, and performance to predicate device (K121404).	Document claims substantial equivalence due to no significant differences raising new safety/effectiveness issues.

2. Sample Size Used for the Test Set and Data Provenance

Sample Size: The document does not specify a "sample size" in terms of number of patients or cases for "testing." Instead, it refers to a series of non-clinical performance tests on the physical device. The number of devices or components tested for each specific bench test (e.g., RBP, fatigue) is not explicitly stated, but it's implied that sufficient numbers were tested to meet the requirements of the ISO standard.
Data Provenance: The data provenance is from non-clinical bench testing of the SoloPath Re-Collapsible Access System itself. It is not human subject data, so concepts of country of origin or retrospective/prospective do not apply.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

This is not applicable as the "ground truth" for non-clinical bench testing is defined by the physical properties of the device and adherence to engineering standards. No human experts were used to establish a "ground truth" for a test set in the way one would for diagnostic imaging.

4. Adjudication Method for the Test Set

Not applicable for non-clinical bench testing. Performance is evaluated against objective engineering specifications and standard test methods.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and Effect Size

No. This is a 510(k) for a physical medical device (catheter introducer) and not an AI/ML product. Therefore, an MRMC study comparing human readers with and without AI assistance is not relevant or included in this document.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

No. This is for a physical medical device. There is no algorithm or AI component involved.

7. The Type of Ground Truth Used

The "ground truth" used for this device's performance testing is based on objective engineering and material specifications, and compliance with recognized industry standards (ISO 10555-4:2013). For example, for "Balloon rated burst pressure," the ground truth is the specified pressure that the balloon must withstand. For "Biocompatibility," the ground truth is compliance with ISO 10993.

8. The Sample Size for the Training Set

Not applicable. There is no "training set" for a physical medical device like this in the context of AI/ML. The device itself is manufactured based on design specifications; it does not "learn" from data.

9. How the Ground Truth for the Training Set Was Established

Not applicable. There is no training set or ground truth established for a training set.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three lines representing its body and wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

January 5, 2016

Onset Medical Corporation % Monika McDole-Russell, MSRA, RAC Senior Regulatory Affairs Specialist Terumo Corporation 265 Davidson Ave. Suite 320 Somerset. NJ 08873

Re: K152498

Trade/Device Name: SoloPath Re-Collapsible Access System Regulation Number: 21 CFR 870.1340 Regulation Name: Catheter Introducer Regulatory Class: Class II Product Code: DYB Dated: December 3. 2015 Received: December 4, 2015

Dear Ms. McDole-Russell:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Isting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in

{1}------------------------------------------------

the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Kenneth J. Cavanaugh -S

for

Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

510(k) Number (if known) K152498

Device Name

SoloPath® Re-Collapsible Access System

Indications for Use (Describe)

The SoloPath® Re-Collapsible Access System is indicated for percutaneous insertion into the femoral artery over a guidewire and, once expanded, to provide a guide for catheters and/or the femoral artery. The device may also be used to expand femoroiliac artery lesions to facilitate its use as an Access System.

Type of Use (Select one or both, as applicable)

X Prescription Use (Part 21 CFR 801 Subpart D)

| Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

{3}------------------------------------------------

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{4}------------------------------------------------

510(k) SUMMARY

A. SUBMITTER INFORMATION (807.92(a)(1))

Prepared by:	Monika McDole-Russell, MSRA, RACSenior Regulatory Affairs SpecialistTerumo Medical Corporation265 Davidson Ave.Suite 320Somerset, NJ 08873Tel. (732) 302-4900 ext. 4273Fax (410) 398-6079
--------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Owner/Operator (Applicant) Prepared for: Onset Medical Corporation 13900 Alton Parkway Suite 120 Irvine, CA 92618 Registration Number: 300467932

Manufacturer

Onset Medical Corporation 13900 Alton Parkway, Suite 120 Irvine, CA 92618 Registration Number: 3004672932

Sterilization Facility Parter Sterilization Services 17115 Kingsview Avenue Carson, CA 90746 Registration Number: 2024311

Contact Person: Monika McDole-Russell, MSRA, RAC

{5}------------------------------------------------

Senior Regulatory Affairs Specialist Terumo Medical Corporation 265 Davidson Ave. Suite 320 Somerset, NJ 08873 Tel. (732) 302-4900 ext. 4273 Fax (410) 398-6079 E-mail: monika.mcdolerussell@terumomedical.com

Date prepared: January 4, 2016

B. DEVICE NAME (807.92(a)(2))

Proprietary Name:	SoloPath® Re-Collapsible Access System
Common Name:	Catheter introducer
Classification Name:	Catheter Introducer
Classification Panel:	Cardiovascular
Regulation:	21 CFR 870.1340
Product Code:	DYB
Classification:	Class II

C. PREDICATE DEVICE (807.92(a)(3))

Substantial equivalence is claimed to the following legally marketed device:

K121404 SoloPath Re-Collapsible Access System, manufactured by ● Onset Medical, California (a division of Terumo Medical Corporation).

D. REASON FOR 510(K) SUBMISSION

This 510(k) is being submitted for:

1. The addition of a secondary indication to the previously cleared indication for the device (K121404).
1. Minor grammatical and punctuation changes to the wording of the primary indication, as depicted in the table below (re-worded section in bold font).

Wording of currently cleared(primary) indication (K121404)	Proposed wording for primaryindication
----------------------------------------------------------------	--------------------------------------------

{6}------------------------------------------------

(K) Summary
The SoloPath Re-Collapsible AccessSystem is intended to be insertedpercutaneously into the femoralartery, over a guidewire and onceexpanded, to provide a guide forcatheters and/or devices introducedinto the femoral artery.	The SoloPath® Re-CollapsibleAccess System is indicated forpercutaneous insertion into thefemoral artery over a guidewire and,once expanded, to provide a guidefor catheters and/or devicesintroduced into the femoral artery.

The changes to the wording are for clarity and conciseness only and do not alter the currently cleared indication for use in any way.

E. DEVICE DESCRIPTION (807.92(a)(4))

F. INTENDED USE (807.92(a)(5))

{7}------------------------------------------------

G. SUBSTANTIAL EQUIVALENCE COMPARISON (807.92(a)(6))

The SoloPath Re-Collapsible Access System, the subject of this Traditional 510(k), is substantially equivalent in its intended use, technology/principal of operation, materials, and performance to K121404 SoloPath Re-Collapsible Access System, manufactured by Onset Medical, California (a division of Terumo Medical Corporation).

The SoloPath Re-Collapsible Access System was cleared for its primary indication via K121404; no significant design, material or manufacturing changes have occurred since that clearance and no changes are being made to the primary indication for intended use as a result of this submission. Therefore, this submission focuses solely on the use of the device for the proposed secondary indication.

A comparison of the intended use/indications for use and technological characteristics relevant to the secondary indication are summarized in the table on the following page. The primary indication is not changing; the secondary indication does not impact the safety and effectiveness of the device; there are no changes to the insertion, deployment, or removal of the device as a result of this secondary indication.

Note: A statement of substantial equivalence to another product is reguired by 21CFR807.87, and relates only to whether the present product can be marketed without prior reclassification or clinical approval. The present submission is, therefore, not related to the coverage of any patent, and is not to be interpreted as an admission or used as evidence in a patent infringement lawsuit. As the Commissioner of the FDA has stated, "…a determination of substantial equivalence under the federal Food, Drug, and Cosmetic Act relates to the fact that the product can lawfully be marketed without pre-market approval or reclassification. This determination is not intended to have any bearing whatever on the resolution of patent infringement 42,520, suits" -----------------------------------------------------------------------------------------------------------------------------------------------------------------------42 Fed. Reg. Reg. (1977)

{8}------------------------------------------------

Table 5.1: Device Comparison Cha

Device Characteristic	Subject Device: SoloPath Re-Collapsible Access System	Predicate: SoloPath Re-Collapsible Access System(K121404)
Manufacturer	Onset Medical, a subsidiary ofTerumo Corporation	Same
Intended Use	The SoloPath® Re-CollapsibleAccess System is indicated forpercutaneous insertion into thefemoral artery over a guidewireand, once expanded, to providea guide for catheters and/ordevices introduced into thefemoral artery. The device mayalso be used to expandfemoroiliac artery lesions tofacilitate its use as an AccessSystem.	The SoloPath® Re-CollapsibleAccess System is intended to beinserted percutaneously into thefemoral artery, over a guidewireand once expanded, to providea guide for catheters and/ordevices introduced into thefemoral artery.
Operation Principle	Manual	Same
Design / Construction	• Sheath assembly (sheath,expander, fairing tip, flushlines, ports, and hemostasisvalve)	• Same

{9}------------------------------------------------

Device Characteristic	Subject Device: SoloPath Re-Collapsible Access System	Predicate: SoloPath Re-Collapsible Access System(K121404)
Materials	Dilator assembly –Polycarbonate,Polypropylene, Siliconerubber, Polycarbonate, Hytrel,PET, Polyurethane, ABS Sheath Assembly – Hytrel,304 stainless steel, Gold,PET, Adhesive,Polycarbonate, Polypropylene Sheath Hemostasis ValveAssembly - Polycarbonate,Silicone, Polypropylene,Adhesive	• Same
Package	Package support (cardboard) Chevron pouch Shelf box	• Same

{10}------------------------------------------------

Device Characteristic	Subject Device: SoloPath Re-Collapsible Access System	Predicate: SoloPath Re-Collapsible Access System(K121404)
Length of inflatable portion (balloon)	20-30 cm (200-300 mm)	Same
Specifications	Recommended Guidewire size	0.038" or smaller
	Maximum Inflated O.D.	28.5 Fr (9.50 mm)¹
	Introducer size/Insertion profile	13.5 -15 Fr²
	Rated Burst Pressure	20 atm (2026 kPa)
	Sterilization	Ethylene Oxide

ximum expanded inflated O.D. provided for SoloPath Re-Collapsible outer sheath. Expander is not intended to be used in patient without the outer sheat 2. Actual insertion profile of the SoloPath Re-Collapsible device

K152498

{11}------------------------------------------------

H. NON CLINICAL TESTS (807.92(b)(1))\

Performance

Performance testing was conducted to demonstrate substantial equivalence tq the predicate device. No new issues of safety and effectiveness were raised during testing.

Terumo consulted ISO 10555-4:2013 Sterile, Single-Use Intravascular Catheters -Part 4: Balloon Dilatation Catheters while preparing this submission and confirmed that all testing applicable to this device was successfully completed (reference Section 18). No deviations from this recognized consensus ISO standard were identified in the testing.

Only those tests pertinent to the secondary indication are discussed in this submission; a brief summary of that testing is included below. Testing is discussed in detail in Section 18 - Performance Testing (Bench).

Table 5.2: Testing Performed on the SoloPath Re-Collapsible Device
--------------------------------------------------------------------	--

Test	Relevant Section of ISO 10555-4
Radio-detectability	Section 4.2
Designation of nominal size	Section 4.3
Balloon rated burst pressure (RBP)	Section 4.4.1, Annex A
Balloon fatigue; freedom from leakage and damage on inflation	Section 4.4.2, Annex B
Balloon deflation time	Section 4.4.3, Annex C

Performance testing demonstrates that the SoloPath Re-Collapsible Access System conforms to the recognized consensus ISO standard, is substantially equivalent to the predicate device, and is acceptable for clinical use throughout the shelf life.

{12}------------------------------------------------

Biocompatibility

No changes have been made to the materials, sterilization process or packaging of the SoloPath Re-Collapsible Access System since the original biocompatibility testing performed in accordance with ISO 10993, the results of which were reviewed under K121404.

Sterilization

The sterility of the device is assured using an overkill/half-cycle sterilization method validated in accordance with ISO 11135-1:2007 Sterilization of health care products -- Ethvlene oxide – Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices. The SoloPath Re-Collapsible Access System is sterilized to provide a Sterility Assurance Level (SAL) of 106.

No changes have been made to the sterilization process or procedure since the device was cleared under K121404.

Risk Analysis

A Product Risk Analysis was conducted in accordance with ISO 14971, taking into account the modifications to the device since clearance under K121404, and it was determined that any new risks were adequately captured and mitigated.

{13}------------------------------------------------

KI"ELINICAL TESTS (807.92(b)(2))

This 510(k) does not include data from clinical tests.

J. CONCLUSION (807.92(b)(3))

In summary, the SoloPath Re-Collapsible Access System, the subject of this 510(k), is substantially equivalent in its intended use, technology/principal of operation, materials, performance and overall clinical utility to K121404 SoloPath Re-Collapsible Access System, manufactured by Onset Medical, California (a division of Terumo Medical Corporation).

There is no significant difference that raises any new issues of safety and effectiveness.

Regulation Number and Section

§ 870.1340 Catheter introducer.

(a)
Identification. A catheter introducer is a sheath used to facilitate placing a catheter through the skin into a vein or artery.(b)
Classification. Class II (performance standards).